Thermo Fisher Launches Global Real-World Registry for Alzheimer’s Disease Research

Thermo Fisher Scientific has enrolled the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry, marking a major step toward building regulatory-grade real-world evidence in Alzheimer’s care.

Why This Registry Matters?

Alzheimer’s disease remains one of the most complex and costly neurological disorders worldwide. Despite recent therapeutic advances, long-term safety and real-world effectiveness data are still limited.

This new registry aims to close that gap.

What the PPD CorEvitas Alzheimer’s Registry Will Do?

The registry is designed as a global, multi-country initiative operating under a common protocol. Its focus is simple: capture how Alzheimer’s therapies perform in real clinical practice.

Key objectives include:

• Tracking long-term drug safety and effectiveness
• Understanding real-world treatment patterns
• Evaluating outcomes linked to approved therapies
• Identifying unmet medical needs across disease stages

The registry uses longitudinal, clinician-reported data, collected during routine care, to reflect how treatments work outside controlled clinical trials.

Safety Monitoring at the Core

A major strength of the registry is its detailed safety assessment framework.

This includes:

• MRI-based monitoring of brain swelling and bleeding
• Evaluation of plaque clearance as a treatment effectiveness marker
• Correlation of biological outcomes with cognitive changes

Together, these data points will help regulators and clinicians better balance benefit versus risk.

Addressing a Growing Public Health Challenge

Alzheimer’s disease affects an estimated 7.2 million Americans aged 65 and older, a number expected to double by 2050.

It is already a leading cause of death in the US. Yet, there is no cure—only therapies that may manage symptoms or slow progression. That makes high-quality real-world evidence essential.

Building Regulatory-Grade Evidence

According to Thermo Fisher, the registry is designed to meet regulatory expectations worldwide.

“We are building a regulatory-grade, real-world evidence foundation that will help shape the understanding of current and next-generation therapies,” said Peter Wahl, Vice President and Global Head of Scientific Affairs, PPD CorEvitas Clinical Registries.

Part of a Larger Registry Ecosystem

The Alzheimer’s registry expands Thermo Fisher’s PPD CorEvitas portfolio, which already includes:

• Over 500 investigator sites globally
• Longitudinal data from more than 100,000 patients
• Proven use in post-authorization safety studies

These registries are already recognized by global regulators.

The Bigger Picture

As Alzheimer’s drug development accelerates, real-world data will increasingly guide:

• Regulatory decisions
• Clinical practice
• Patient and caregiver expectations

With this registry, Thermo Fisher is positioning itself at the center of that evidence ecosystem.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!